Edgewise Therapeutics Inc
EWTX14.017USD
-0.133-0.94%
交易中 （美东）报价延迟15分钟
1.48B总市值
亏损市盈率 TTM
关于 Edgewise Therapeutics Inc 公司
Edgewise Therapeutics, Inc. 是一家肌肉疾病生物制药公司，致力于开发治疗肌营养不良症和严重心脏病的新型疗法。该公司的主要候选产品 sevasemten (EDG-5506) 是一种口服骨骼肌球蛋白抑制剂，目前正在进行贝克尔和杜氏肌营养不良症的后期临床试验。其 EDG-7500 是一种新型心脏肌节调节剂，用于治疗肥厚性心肌病和其他舒张功能障碍疾病，目前处于 II 期临床开发阶段。该公司正在利用其专有的药物发现平台开发一系列精准医疗候选产品，这些产品针对关键的肌肉蛋白和调节剂，以解决各种严重的肌肉疾病。其平台利用定制的高通量和可转化系统测量整个器官提取物中的综合肌肉功能，以识别调节肌肉组织中关键蛋白质的小分子精准药物。
公司简介
公司代码EWTX
公司名称Edgewise Therapeutics Inc
上市日期Mar 26, 2021
CEODr. Kevin Koch, Ph.D.
员工数量110
证券类型Ordinary Share
年结日Mar 26
公司地址1715 38Th St
城市BOULDER
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编80301
电话17202627002
网址https://edgewisetx.com/
公司代码EWTX
上市日期Mar 26, 2021
CEODr. Kevin Koch, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
369.40K
+2.78%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.41K
+13.58%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
23.64K
+16.16%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
12.27K
+7.52%
Mr. John R. Moore
Mr. John R. Moore
General Counsel
General Counsel
5.03K
+273.83%
Dr. Alan Russell, Ph.D.
Dr. Alan Russell, Ph.D.
Chief Scientific Officer, Director, Co-Founder
Chief Scientific Officer, Director, Co-Founder
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
369.40K
+2.78%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.41K
+13.58%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
23.64K
+16.16%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
12.27K
+7.52%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
OrbiMed Advisors, LLC
14.73%
RA Capital Management, LP
9.40%
Baker Bros. Advisors LP
6.94%
Paradigm BioCapital Advisors LP
5.83%
Janus Henderson Investors
5.22%
其他
57.88%
持股股东
持股股东
占比
OrbiMed Advisors, LLC
14.73%
RA Capital Management, LP
9.40%
Baker Bros. Advisors LP
6.94%
Paradigm BioCapital Advisors LP
5.83%
Janus Henderson Investors
5.22%
其他
57.88%
股东类型
持股股东
占比
Hedge Fund
26.25%
Investment Advisor
21.79%
Private Equity
21.25%
Investment Advisor/Hedge Fund
19.40%
Venture Capital
14.90%
Research Firm
1.97%
Individual Investor
0.51%
Pension Fund
0.24%
Bank and Trust
0.17%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
392
106.86M
101.57%
-4.27M
2025Q1
393
107.86M
104.23%
-2.02M
2024Q4
367
101.45M
106.62%
-4.12M
2024Q3
338
103.17M
110.02%
-3.61M
2024Q2
297
103.29M
110.57%
-1.75M
2024Q1
271
99.64M
106.68%
+5.45M
2023Q4
244
81.22M
115.32%
+5.36M
2023Q3
218
69.97M
110.26%
-9.47M
2023Q2
215
71.14M
112.43%
-5.61M
2023Q1
210
68.18M
108.02%
-8.97M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
OrbiMed Advisors, LLC
15.25M
14.5%
-265.63K
-1.71%
May 12, 2025
RA Capital Management, LP
8.91M
8.47%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
6.16M
5.85%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
4.39M
4.18%
-344.37K
-7.27%
Mar 31, 2025
Janus Henderson Investors
5.28M
5.02%
+298.21K
+5.98%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.39M
5.13%
+31.84K
+0.59%
Mar 31, 2025
Novo Holdings A/S
5.35M
5.09%
+350.00K
+7.00%
Mar 31, 2025
Braidwell LP
2.46M
2.34%
+126.61K
+5.43%
Mar 31, 2025
The Vanguard Group, Inc.
4.29M
4.07%
-172.44K
-3.87%
Mar 31, 2025
Perceptive Advisors LLC
6.55M
6.22%
+1.38M
+26.78%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月6日 周三
更新时间: 8月6日 周三
机构名称
占比
iShares Neuroscience and Healthcare ETF
2.7%
SPDR S&P Pharmaceuticals ETF
2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.27%
ALPS Medical Breakthroughs ETF
0.93%
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
iShares U.S. Pharmaceuticals ETF
0.49%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares Health Innovation Active ETF
0.17%
First Trust Multi-Manager Small Cap Opportunities ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
查看更多
iShares Neuroscience and Healthcare ETF
占比2.7%
SPDR S&P Pharmaceuticals ETF
占比2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.27%
ALPS Medical Breakthroughs ETF
占比0.93%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.77%
iShares U.S. Pharmaceuticals ETF
占比0.49%
Federated Hermes MDT Small Cap Core ETF
占比0.3%
iShares Health Innovation Active ETF
占比0.17%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.15%
ProShares Ultra Nasdaq Biotechnology
占比0.15%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
